Bailard Inc. lessened its holdings in shares of MEI Pharma Inc (NASDAQ:MEIP) by 7.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 381,292 shares of the company’s stock after selling 28,708 shares during the quarter. Bailard Inc. owned about 0.54% of MEI Pharma worth $1,007,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the business. Dimensional Fund Advisors LP boosted its position in MEI Pharma by 4.1% during the second quarter. Dimensional Fund Advisors LP now owns 445,698 shares of the company’s stock worth $1,756,000 after purchasing an additional 17,562 shares during the period. Renaissance Technologies LLC boosted its position in MEI Pharma by 0.8% during the third quarter. Renaissance Technologies LLC now owns 2,236,480 shares of the company’s stock worth $9,639,000 after purchasing an additional 17,667 shares during the period. Virtu Financial LLC purchased a new stake in shares of MEI Pharma in the third quarter worth about $232,000. Wasatch Advisors Inc. lifted its holdings in shares of MEI Pharma by 23.8% in the third quarter. Wasatch Advisors Inc. now owns 315,130 shares of the company’s stock worth $1,358,000 after buying an additional 60,653 shares in the last quarter. Finally, Monashee Investment Management LLC purchased a new stake in shares of MEI Pharma in the third quarter worth about $322,000. Hedge funds and other institutional investors own 51.40% of the company’s stock.
A number of equities research analysts have recently issued reports on MEIP shares. reissued a “buy” rating and issued a $7.50 price target on shares of MEI Pharma in a report on Friday, November 9th. Zacks Investment Research downgraded shares of MEI Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, November 14th. Finally, HC Wainwright started coverage on shares of MEI Pharma in a report on Thursday, December 20th. They issued a “buy” rating and a $10.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. MEI Pharma currently has a consensus rating of “Buy” and an average price target of $8.08.
MEI Pharma (NASDAQ:MEIP) last announced its earnings results on Thursday, February 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $2.05 million during the quarter, compared to analysts’ expectations of $3.05 million. MEI Pharma had a negative net margin of 1,454.51% and a negative return on equity of 77.29%. As a group, research analysts predict that MEI Pharma Inc will post -0.6 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2019/02/12/bailard-inc-cuts-holdings-in-mei-pharma-inc-meip.html.
About MEI Pharma
MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Recommended Story: What is the S&P 500 Index?
Want to see what other hedge funds are holding MEIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEI Pharma Inc (NASDAQ:MEIP).
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.